Clinical trials: HIV Coinfection
HIV Infections, HIV-HBV Co-Infection
HIV-HBV Co-Infection and Liver Disease
Human immunodeficiency virus/Hepatitis B virus (HIV/HBV) co-infections are frequently observed due to shared routes of transmission, with reported figures indicating 6-9% of HIV-infected individuals in developed countries are…
- Trial name
- NCT00637429
- Where
- Australia
- Volunteers
- 70 people
- Sponsor
- Bayside Health
Hepatitis, Hepatitis C
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1…
- Conditions
- Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
- Trial name
- NCT02103439
- Testing
- Algeron, PegIntron
- Where
- 6 sites in Russia
- Volunteers
- 140 people
- Sponsor
- Biocad
HIV Infections, SARS-CoV-2 Infection
COVID-19 Serology in People Living with HIV in Hong Kong
Immunodeficiency associated with human immunodeficiency virus (HIV) infection could predispose people living with HIV/AIDS (PLHA) to defective serological responses following infection or vaccination.
- Conditions
- HIV Infections, SARS-CoV-2 Infection, Vaccination; Infection
- Trial name
- NCT05028881
- Testing
- blood sampling
- Where
- China
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
HIV Infection, Hepatitis C Infection
Study on Immunopathogenesis in HIV and Hepatitis C Coinfection
Liver-related death is the leading cause of mortality in HIV-infected individuals with CD4+ cell counts over 200, and hepatitis C virus (HCV) infection is the greatest risk for liver-related mortality in HIV-positive patients.
- Conditions
- HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
- Trial name
- NCT01296529
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Rush University Medical Center
HIV, Hepatitis B
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
The EuroSIDA study is a prospective observational cohort study of 23,000+ patients followed in 100+ clinics in 35 European countries, Israel and Argentina.
- Conditions
- HIV, Hepatitis B, Hepatitis C, AIDS
- Trial name
- EuroSIDA (NCT02699736)
- Where
- 110 sites in Argentina, Austria and 34 more
- Volunteers
- 23,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chronic Hepatitis C
Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection
This clinical study will evaluate whether grazoprevir and elbasvir is efficacious, safe, and well-tolerated in peginterferon alfa plus ribavirin experienced patients who inject drugs (PWID) and men who sex with men (MSM) with…
- Trial name
- NCT03098121
- Testing
- grazoprevir and elbasvir
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Taoyuan General Hospital
Hemophilia, AIDS
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
Background: Over 80% of the hemophiliac population who became infected with HIV prior to 1985 are also co-infected with HCV. Thus, hemophiliacs represent an important population for studies of the natural history of these chronic…
- Trial name
- NCT00340548
- Where
- 15 sites in United States
- Volunteers
- 333 people
- Sponsor
- National Cancer Institute (NCI)
Infection, Human Immunodeficiency Virus, HIV Infections
Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
HIV/Tuberculosis (TB) co-infection have profound effects on the host's immune system. TB is the most common cause of death in patients with HIV worldwide.
- Trial name
- NCT02178592
- Testing
- DTG 50 mg, EFV 600 mg
- Where
- 28 sites in Argentina, Brazil and 5 more
- Volunteers
- 113 people
- Sponsor
- ViiV Healthcare
HIV Infection, Hepatitis C
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
The chief purpose of this research is to understand how antiretroviral therapy (ART) affects progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV).
- Trial name
- NCT01423643
- Where
- United States
- Volunteers
- 1,250 people
- Sponsor
- Johns Hopkins University
HCV Coinfection, Liver Disease
deLIVER: Direct Acting Antiviral Effects on the Liver
Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting…
- Conditions
- HCV Coinfection, Liver Disease, HIV
- Trial name
- deLIVER (NCT02938013)
- Testing
- Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Liver Cirrhosis
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
- Trial name
- OP-724-H202 (NCT07681089)
- Testing
- Foscenvivint
- Where
- 4 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Kiminori Kimura, MD
HIV, Hepatitis-B
HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection
The trial will randomise HIV/HBV co-infected individuals to different HBV-active antiretroviral therapy treatment regimens.
- Trial name
- NCT00476723
- Where
- Thailand
- Volunteers
- 36 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Leishmaniasis, Visceral
Predicting Visceral Leishmaniasis in HIV Infected Patients
In this cohort study, the investigators will study the asymptomatic period preceding the onset of active Visceral Leishmaniasis (VL) in HIV-infected individuals from VL endemic regions in Ethiopia as an avenue to develop an…
- Trial name
- PreLeisH (NCT03013673)
- Testing
- No intervention
- Where
- Ethiopia
- Volunteers
- 566 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Liver Cirrhosis
A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
This is a phase 2 trial of foscenvivint in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia to evaluate the efficacy, safety and pharmacokinetics.
- Trial name
- NCT06144086
- Testing
- Foscenvivint
- Where
- 3 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Kiminori Kimura, MD